Metabolic Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms of PPARα are of interest in order to improve our understanding of metabolic disorders associated with a raised or reduced risk of diseases.
|
31489930 |
2019 |
Metabolic Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results suggest that a targeted therapeutic approach for enhanced PPARα and lipolysis may reduce HCV genotype-associated lipid metabolic disorder in liver disease.
|
31243135 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear hormone receptor that transcriptionally regulates lipid metabolism and inflammation; therefore, PPARα agonists are promising agents to treat dyslipidemia and metabolic disorders.
|
30648583 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
PPAR receptors play a critical role in metabolic disorders, affecting glucose and lipid metabolism.
|
31009912 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Aqueous Extract of Black Maca Prevents Metabolism Disorder via Regulating the Glycolysis/Gluconeogenesis-TCA Cycle and PPARα Signaling Activation in Golden Hamsters Fed a High-Fat, High-Fructose Diet.
|
29681858 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The action of wistin on PPARα could be of interest for the amelioration of lipid metabolic disorders.
|
29318455 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
|
29224415 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, acquisition of rhythmicity for non-core clock components PPARα and SREBP1 remodels metabolic gene transcription in response to overnutrition and enables a chronopharmacological approach to metabolic disorders.
|
30057115 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, certain PTMs in PPAR proteins have been associated with the status of metabolic diseases.
|
29895749 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator-activated receptor beta/delta (PPARß/<i>δ</i>) is considered a therapeutic target for metabolic disorders, cancer, and cardiovascular diseases.
|
29849537 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component.
|
30020428 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The PGC-1α/PPAR axis has been proposed as a potential therapeutic target for several metabolic disorders.
|
28279226 |
2017 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the molecular mechanisms underlying PPARα activator-mediated reduction in adiposity and improvement of metabolic disorders are largely unknown.
|
28404815 |
2017 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator-activated receptor α (PPARα) plays a key role in lipid metabolism and glucose homeostasis and a crucial role in the prevention and treatment of metabolic diseases.
|
27863018 |
2017 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
It is concluded that combined DHA-T<sub>3</sub> supplementation achieves synergistic effects on liver PPARα-FGF21-AMPK signaling, which may result in significant metabolic changes associated with energy expenditure that are of importance in the treatment of obesity and other metabolic disorders.
|
28990606 |
2017 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggested that the induction potential of CYPs was suppressed by activated PPARα, showing a potential role of this receptor in drug-drug interactions and metabolic diseases treated with fibrates.
|
28374976 |
2017 |
Metabolic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ.
|
28185575 |
2016 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Natural compounds that regulate peroxisome proliferator-activated receptor alpha (PPARα) have been reported to have beneficial effects in obesity-mediated metabolic disorders.
|
27145114 |
2016 |
Metabolic Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight single nucleotide polymorphisms in the PPARα gene were chosen from either the HapMap CHB database or previous reports.The distribution of metabolic disorders differed significantly between the wild-type and variant genotypes of both the rs5767743 and rs5767700 loci (P < 0.05 for all).
|
26334901 |
2015 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
LHGDN |
This Review will focus on the mechanisms of action of PPARalpha in metabolic diseases and their associated vascular pathologies.
|
16511589 |
2006 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The peroxisome proliferator-activated receptor-gamma2 (PPAR(gamma2)) represents the transcriptional master regulator of adipocyte differentiation and therefore has been suggested as candidate gene for the pathogenesis of obesity, type 2 diabetes and related metabolic disorders.
|
11928067 |
2002 |